価格表

在庫・価格 : 2024年04月26日 01時35分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Human/Cynomolgus Monkey B7-H1/PD-L1 Quantikine ELISA Kit
データシート※最新のデータシートでない場合があります
DB7H10 RSDアールアンドディー システムス
R&D Systems, Inc.
1 kit ¥116,000 1個 追加

在庫・価格 : 2024年04月26日 01時35分 現在

Human/Cynomolgus Monkey B7-H1/PD-L1 Quantikine ELISA Kit

  • 商品コード:DB7H10
  • メーカー:RSD
  • 包装:1kit
  • 価格: ¥116,000
  • 在庫:1個
使用文献
No. 文献情報 備考 参照
1 Jin J et al. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. Respir. Res. 2018 Oct;19(1):197
Jin J et al
2018/01/01
PubMed
2 Kim HJ et al. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiother Oncol 2018 10;129(1):130-135
Kim HJ et al
2018/01/01
PubMed
3 Yang J et al. Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma. Oncol Lett 2019 Mar;17(3):3382-3386
Yang J et al
2019/01/01
PubMed
4 Mocan T et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol 2021 May;94:107467
Mocan T et al
2021/01/01
Species: Human PubMed
5 Chiarucci C et al. Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. Cancers (Basel) 2020 Feb;12(2)
Chiarucci C et al
2020/01/01
Species: Human PubMed
6 Fei Y et al. Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. J Cancer 2020;11(23):7001-7008
Fei Y et al
2020/01/01
Species: Human PubMed
7 Xu J et al. Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages. Cell Death Dis 2020 10;11(10):934
Xu J et al
2020/01/01
Species: Human PubMed
  • No.: 1
  • 文献情報:
    Jin J et al. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. Respir. Res. 2018 Oct;19(1):197
    Jin J et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Kim HJ et al. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiother Oncol 2018 10;129(1):130-135
    Kim HJ et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Yang J et al. Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma. Oncol Lett 2019 Mar;17(3):3382-3386
    Yang J et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Mocan T et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol 2021 May;94:107467
    Mocan T et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Chiarucci C et al. Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. Cancers (Basel) 2020 Feb;12(2)
    Chiarucci C et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Fei Y et al. Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. J Cancer 2020;11(23):7001-7008
    Fei Y et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Xu J et al. Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages. Cell Death Dis 2020 10;11(10):934
    Xu J et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed